Eli Lilly is trading 3% down at $1114.17 on profit-taking and consolidation following a strong multi-month rally and recent sector-wide volatility.
- The move appears to be a technical pullback rather than a reaction to fresh news, as no new earnings, FDA decisions, or major announcements have been reported.
- Today's decline comes despite broader market strength, with major indices trading up over 1%.